Study shows potential of anti-growth factor drugs for reducing complication of advanced ovarian cancer
Tuesday, December 20, 2011 - 18:30
in Health & Medicine
Blocking the action of vascular endothelial growth factor (VEGF) with the new anti-VEGF drug aflibercept can curb the development of malignant ascites (excessive fluid in the abdomen), a common and painful complication of advanced ovarian cancer, according to a new phase 2 randomised study published Online First in the Lancet Oncology.